Today, during the annual "JPM Week" in San Francisco, CEO, David “DSO” Suendermann-Oeft, PhD participated in a panel discussion "What is TechBio and What Impact Will It Have on Therapeutic Development?"
Curious about what it takes to build a startup at the intersection of AI and medicine? Our visionary CEO, David “DSO” Suendermann-Oeft, PhD, shares his rich tapestry of roles as researcher, professor, founder, scientist, and musician...
https://t.co/0nFbyE8DLP
This week, our Chief Operating Officer, Lakshmi Arbatti, and Data Scientist, Abhishek Hosamath, presented their work at the Parkinson Study Group Annual Meeting in Tennessee. #pd#Parkinsons#ClinicalTrials https://t.co/YmrPCpjAKw
Modality Presents at Parkinson Study Group Annual Meeting: This week, our COO, Lakshmi Arbatti, and Data Scientist, Abhishek Hosamath, are presenting their work at the Parkinson Study Group Annual Meeting in Tennessee. https://t.co/gztWjI7R7L
Modality’s CEO David "DSO" Suendermann-Oeft and Senior Research Scientist Hardik Kothare to present our work on "Multimodal Speech Biomarkers for Remote Monitoring of ALS Disease Progression" at the 7th Annual ALS Research Symposium. https://t.co/eQwuDDNfYv
@TargetALS_fdn, the global foundation for ALS research, is partnering with https://t.co/7dp5ckjj1z to launch a groundbreaking direct-to-participant study. https://t.co/8obS6OKKez
*Five New ALS Publication Acceptances* At https://t.co/7dp5ckjj1z, ALS remains at the very heart of our mission, so we're pleased to share that our research has recently been recognized with five new presentations at three seminal ALS conferences. https://t.co/YmrPCpjAKw
@TargetALS_fdn is partnering with https://t.co/7dp5ckjj1z to launch a groundbreaking direct-to-participant study, utilizing Modality's innovative digital health platform to monitor disease progression in ALS patients. https://t.co/8obS6OKKez
Attending the International Congress of Parkinson's Disease and Movement Disorders®? We invite you to connect with Modality's Head of Science Sales, Meredith Bartlett. https://t.co/9aijG1BstU
New Publication: Multimodal Technologies for Remote Assessment of Neurological and Mental Health. The article reviews the advantages of using multimodal technologies for remote neurological and mental health assessment. #ClinicalTrials https://t.co/fxFBbdPYG0
How can we capture a fuller picture of patient experiences in clinical trials? Find out now through this recording of a recent Modality webinar in which we discuss the Patient Report of Problems. https://t.co/ve3KrtCFkD
Our CEO, David Suendermann-Oeft, will attend the Digital Biomarkers in Clinical Trials Summit on June 26, 2024, at Roche Headquarters in Basel. Be sure to connect if you’re attending.
https://t.co/QLroBVZZl8
This week, June 17-20, https://t.co/7dp5ckjj1z CEO David "DSO" Suendermann-Oeft will attend and present at the ENCALS Meeting in Stockholm. ENCALS is a network of European universities and hospital centers active in clinical/research activities in ALS. https://t.co/52wudDrVtu
Ahead of ENCALS he will attend a meeting hosted by Precision ALS, a pan-European organization working to build a “Patient Data Platform” so that research sites across Europe can work together towards a common goal of finding a treatment for ALS. https://t.co/MFLwpU8Ot5
Will you be at #BIO in San Diego? Let's meet! Our CEO, David Suendermann-Oeft (DSO) is sharing an update on https://t.co/7dp5ckjj1z on Wednesday, June 5th at 2.45pm in Presentation Room 4. DSO will also present on Thursday afternoon in the NIH booth.
#BIOInternationalConvention